Welcome to our dedicated page for Zevra Therapeutics news (Ticker: ZVRA), a resource for investors and traders seeking the latest updates and insights on Zevra Therapeutics stock.
Zevra Therapeutics reports developments as a commercial-stage biopharmaceutical company focused on therapies for rare diseases. Recurring updates center on MIPLYFFA (arimoclomol), its U.S.-approved treatment for Niemann-Pick disease type C, including commercialization, patient access, regulatory activity and diagnostic-support initiatives tied to NPC.
Zevra news also covers financial results, pipeline programs in rare diseases such as vascular Ehlers-Danlos syndrome, and corporate actions that shape its portfolio. Recent company updates include the completed sale of the serdexmethylphenidate, or SDX, portfolio, including AZSTARYS and KP1077, as well as governance and executive-compensation announcements under Nasdaq rules.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) announced the submission of an IND application to the FDA to initiate a Phase 1 clinical trial for KP1077 in narcolepsy. This expands the ongoing Phase 2 trial for idiopathic hypersomnia (IH), with data potentially leading to pivotal Phase 3 studies for both conditions. The FDA confirmed no additional non-clinical studies are needed for KP1077, which is based on the established compound serdexmethylphenidate. Zevra is focused on advancing therapies for rare diseases and previously received various designations for its product Arimoclomol to treat Niemann-Pick disease type C.
Zevra Therapeutics (NasdaqGS: ZVRA) announced the appointment of Wendy L. Dixon, Ph.D., to its Board of Directors, effective immediately after the 2023 Annual Meeting on April 25, 2023. This follows the resignation of Dr. Travis Mickle, who co-founded Zevra. Dr. Dixon, with over 40 years of biopharma experience, previously held senior roles at Bristol Myers Squibb and Merck. Chairman Matthew Plooster emphasized her extensive industry experience as Zevra focuses on rare diseases. Dr. Dixon expressed excitement about contributing to Zevra's mission to provide solutions for patients with rare diseases.